ClinicalTrials.gg
Drug

Sugammadex clinical trials

Also written Bridion, Org 25969 and MK-8616.

studies test it
201
open now
15
in phase 3
36
first study started
2002

How each study uses Sugammadex is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Sugammadex studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
15 Dec 2015 · BRIDION · NDA 022225 (FDA, Drugs@FDA)
European Union
25 Jul 2008 · Bridion · EMEA/H/C/000885 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Sugammadex
155
Sugammadex 4 mg/kg
8
Sugammadex 2 mg/kg
7
Sugammadex Sodium
6
Sugammadex Injection [Bridion]
4

Brand

Bridion
72

Development codes

Org 25969
29
MK-8616
20
SCH 900616
7
SCH 900916
1

In one entry with another drug

Given together, or one or the other

Rocuronium + sugammadex
3
Rocuronium and Sugammadex
2

Studies by the year they started

201 studies that test it; most in 2017 (21)

Studies that test Sugammadex, by start year
YearStudies
20021
20031
20042
200512
20062
20071
20086
20092
20106
20119
20129
20138
201412
201513
20168
201721
201815
201914
20208
202110
20227
202313
202413
20254
20264

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
8
Phase 2
22
Phase 3
36
Phase 4
95
No phase
44

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 41 · Other 160

Merck Sharp & Dohme LLC (39) · Seoul National University Hospital (6) · Seoul National University Bundang Hospital (5) · Guangzhou General Hospital of Guangzhou Military Command (4) · University of Texas Southwestern Medical Center (4) · Ajou University School of Medicine (4) · West Virginia University (3) · Mansoura University (3)

Often tested with

Tested in the same studies.

Neostigmine (37) · Rocuronium (23) · Glycopyrrolate (10) · Atropine (4) · Vecuronium (3) · Succinylcholine (3) · Cisatracurium (2) · Pyridostigmine (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 5, 1 in phase 3

Studies that test Sugammadex, phase 3 first.

Studies

Open first, then newest update. How each study uses Sugammadex is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 201

See all 201 studies that test Sugammadex →

Given beside what is tested · 8 — Sugammadex is usual care or a partner of the new treatment
As the comparator · 4 — what is tested is compared with Sugammadex

Codes

What other systems call Sugammadex · ClinicalTrials.gg INT006645

  • MeSH (NLM) D000077122SugammadexConfirmed NLM, Wikidata
  • UNII (FDA) 361LPM2T56SUGAMMADEXConfirmed FDA, NLM, Wikidata
  • RxNorm 1726988Confirmed FDA, Wikidata
  • Wikidata Q81987842sugammadexConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C80629SugammadexOne source FDA
  • DrugBank DB06206One source Wikidata

Also registered as sugammadex sodium (UNII ERJ6X2MXV7 · RxNorm 1726987).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.